Top Pick DetailsFirst stock in the clip. He doesn't mince words as earlier in the show, he trashed Organigram. He also owns it personally as well as in his fund. GLTA
https://www.bnnbloomberg.ca/video/brian-madden-s-top-picks~2194811
Curaleaf Holdings (CURA CSE) latest purchase April, 2021 @ $16.59
Curaleaf Holdings is the world’s largest producer of marijuana, as measured by sales. Operating entirely in the United States and in Europe but listed in Canada, Curaleaf is vertically integrated with a presence in 23 states and five western European countries, including 24 cultivation sites, 30 processing facilities and 106 dispensaries. The company is growing rapidly, both organically with many new dispensaries opened in recent quarters and with licenses to open a further 29 stores, as well as via acquisitions. The company is leveraging its roots in medicinal marijuana and moving into recreational marijuana as more and more states, including five more in November via ballot initiatives in the U.S. election, legalize marijuana. Unlike the Canadian market which is oversupplied and where the regulated market is struggling to compete with the black market, the United States market is undersupplied. And perhaps most importantly, unlike the vast majority of Canadian marijuana producers, Curaleaf has a sound strategy, a strong board and management team and excellent corporate governance and management-shareholder alignment.
TOP PICK
Curaleaf Holdings Inc.
(CURA-C)
May 4, 2021
His pick in cannabis (the complete opposite to Organigram). They're a Canadian company but they operate entirely in the U.S., and (after a recent $300 million purchase) five western European countries. In terms of cannabis legalization, Europe is roughly where the U.S. was three years ago. He alsolikes that they're vertically integrated with 23 cultivation sites, 24 processing ones, and 106 dispensaries with licenses to add 30 across 23 American states. He likes that they're leveraging their roots in medical MJ, branching into the bigger recreational market. They rise above other cannabis companies by offering good governance, sound strategy and executive ownership of shares. Checks all the boxes. (Analysts’ price target is $28.02)
Brian Madden
Price
$18.24
Owned
Yes